{"id":"W3129156895","doi":"10.1161/jaha.120.019238","title":"Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF","year":2021,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Université de Montréal; Montreal Heart Institute","funders":"Relypsa; Regeneron Pharmaceuticals; National Institutes of Health; MyoKardia; Novo Nordisk; Daiichi Sankyo Europe; Gilead Sciences; Servier; University of Glasgow; British Heart Foundation; Cytokinetics; Ironwood Pharmaceuticals, Incorporated; National Heart, Lung, and Blood Institute; Sun Pharma; Defense Acquisition Program Administration; Boston Scientific Corporation; Alnylam Pharmaceuticals; Sanofi; GlaxoSmithKline; Celladon Corporation; Amgen; Vifor Pharma; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ejection fraction; COPD; Heart failure; Internal medicine; Cardiology; Hazard ratio; Enalapril; Valsartan; Natriuretic peptide; Heart failure with preserved ejection fraction; Angiotensin-converting enzyme; Confidence interval; Blood pressure","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000135128,0.000110968,0.0005749602,0.00005468797,0.00007737317,0.0000199068,0.00002204479,0.00003680485,0.000006508379],"category_scores_gemma":[0.0001901357,0.00006539008,0.00009713731,0.0001692033,0.00007902575,0.0001706185,0.0000224324,0.0002115807,7.15934e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002957481,"about_ca_system_score_gemma":0.0001600348,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003121503,"about_ca_topic_score_gemma":0.00001923499,"domain_scores_codex":[0.998784,0.0002183672,0.0003545793,0.0001458138,0.0003963526,0.0001008991],"domain_scores_gemma":[0.9985671,0.0002217271,0.0007024302,0.0001380097,0.0002605467,0.0001101724],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000473806,0.0002495104,0.9969066,0.00001482897,0.0004151134,0.000006682307,0.00004528561,0.000001481295,0.0003961977,0.000003563863,0.0003154885,0.001171397],"study_design_scores_gemma":[0.001107582,0.0005657754,0.9938498,0.0001101247,0.0006660961,0.000007964538,0.0001603617,0.00002696596,0.0001177785,0.0000428193,0.003277959,0.00006681761],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930274,0.00008367763,0.00002983527,0.006499264,0.0001213596,0.0002126879,0.00001306078,0.000006111704,0.000006578764],"genre_scores_gemma":[0.9980425,0.00008684993,0.001365803,0.000245847,0.0001667773,0.00000309573,0.00001758592,0.00001154724,0.0000600414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006253417,"threshold_uncertainty_score":0.266653,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008678459535362894,"score_gpt":0.2691748798920032,"score_spread":0.2604964203566403,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}